CHARLES RIVER ACQUIRES DISTRIBUTED BIO
This acquisition allows us to offer an integrated, end-to-end platform for therapeutic antibody discovery and development.
WHAT WE DO
ABOUT US
We are computational immuno-engineers. Our mission is to create breakthrough technologies to drug previously challenging targets (GPCRs, ion channels, pMHC complexes, condition-specific binders, anti-idiotypes, and broadly neutralizing viral epitopes). In monoclonal therapeutics, our integration of computational immunology, bioengineering and robotics has enabled us to create a pipeline of molecules with unprecedented biophysical properties, while also supporting all of our partners with thousands of high affinity developable antibodies against any drug target of interest.
OUR APPROACH
TECHNOLOGIES
discover with
SuperHuman
discover with
Tungsten
Years of camelid repertoire analysis inform a computationally optimized synthetic single domain library.
analyze with
AbGenesis
A field-leading cloud-based computational platform for antibody repertoire analysis.
engineer with
Tumbler
Creates billions of variants of a starting antibody to find improvements and remarkable therapeutic properties.
The world’s most advanced computationally optimized human antibody library for antibody discovery.
Need amazing antibodies? Get in touch to help us discover your next therapeutic.